We are a biotechnology venture company founded with patented techniques based on the mycoplasma lipid antigen.
We are attempting to overcome mycoplasma infection leading to chronic or intractable disease. This is done by putting techniques based on the mycoplasma lipid antigen, which the founder has studied, to practical use for development of a vaccine and diagnostic agent. The lipid antigen is a patented substance, and has already been registered in Japan and abroad. The diagnostic agent has been placed on the Japanese market and can be internationally ordered. We have already applied for an international patent for the vaccine, and we are now in negotiations to prepare the vaccine for the Japanese, US, and European markets.
We are putting techniques based on the mycoplasma lipid antigen to practical use for the development of a vaccine and diagnostic agent. Founder Kazuhiro Matsuda has been studying these techniques since before the foundation of the company. Our aim is to overcome mycoplasma infection leading to chronic or intractable disease. The lipid antigen is a patented substance and has already been registered in Japan and overseas. The diagnostic agent produced with this lipid antigen for research and examination has been placed on the Japanese market. We have prepared a system for receiving international orders. Moreover, we have developed a mycoplasma infection vaccine, for which we have filed an international patent application. We are now negotiating with authorities, companies, and investors to prepare the vaccine for the Japanese, US, and European markets.
Housing grant in the second half of FY 2012 by Himawari High-Tech Venture Development Foundation (Public Interest Incorporated Foundation).
|Company name||M Bio Technology Inc.|
|Representative name||Kazuhiro Matsuda|
|Representative position name||President|
ZIP Cpde 158-0081
2-1-3-1103, Fukazawa Setagaya-ku Tokyo
|Other sites||Mycoplasma Infectious Diseases Research Center|
|Transaction performance (domestic)||We have already received orders for the mycoplasma lipid antigen/antibody test from a number of clinics and university hospitals through our analysis center.|
|Transaction performance (overseas)||We are now negotiating with overseas companies, universities, and so on.|
|Bio Japan 2013; BIO Europe Spring 2013; Bio Japan 2014 (scheduled); Biotech Showcase 2014; BIO Europe Spring 2014 (scheduled).|